logo
Alice Figueiredo death: NHS trust and medic guilty of failings

Alice Figueiredo death: NHS trust and medic guilty of failings

BBC News09-06-2025

A hospital trust and a staff member have been found guilty of health and safety failings over the death of a young woman in a mental health unit.Alice Figueiredo, 22, was being treated at Goodmayes Hospital, east London, when she took her own life in July 2015, having previously made many similar attempts.Following a seven-month trial at the Old Bailey, a jury found that not enough was done by the North East London Foundation NHS Trust (NELFT) or ward manager Benjamin Aninakwa to prevent Alice from killing herself.The trust was cleared of the more serious charge of corporate manslaughter, while Aninakwa, 53, of Grays in Essex, was cleared of gross negligence manslaughter.
The jury deliberated for 24 days to reach all the verdicts, setting a joint record in the history of British justice, according to the Crown Prosecution Service. It was only the second time an NHS trust has faced a corporate manslaughter charge. Speaking directly to Alice's mother and stepfather after the verdict, Judge Richard Marks KC said it was clear from the evidence that she was an extremely special young woman and "their immense love for her had been very apparent". He also said he hoped they felt the case had been dealt with fully and that would "provide some consolation".
This article contains material that some may find distressing.If you are affected by any of the issues raised in this story, support and advice is available via the BBC Action Line.
Alice was admitted to a mental health ward at Goodmayes Hospital in Ilford in February 2015.She was under close observation on the Hepworth Ward, then managed by Aninakwa.In the five months leading up to her death, she attempted suicide using plastic or bin bags on 18 occasions, mostly taking bin bags from the same shared toilet, the Old Bailey heard.The hospital had previously acknowledged the risk to patients of keeping bin bags on the ward and they were subsequently taken out of patient bedrooms.However, despite warnings from Alice's family, they were not removed from the communal toilet, which was left unlocked.On 7 July 2015, at her 19th attempt, she took her own life using a bin bag taken from the toilet.During the trial, prosecutors said that not only was Alice repeatedly able to self-harm while she was in hospital, but that these incidents were not properly recorded or assessed.
The court also heard there were concerns about Aninakwa's communication, efficiency, clinical and leadership skills.The trust had previously placed him on a performance improvement plan for three years, which ended in December 2014.In addition, there was a high turnover of agency staff on the ward, the court heard.
Alice's mother Jane Figueiredo described the "intense pain" of being told about her death, saying it was the moment when "your entire life changes forever".Her family prefer to remember the clever, creative, musical and funny young woman, who they say was full of life."She had the most amazing quick wit and sense of humour," Mrs Figueiredo said."She used to be able to make me laugh more than anybody in the world. And I really miss that."Alice had experienced periods of deep depression since she was a teenager and also developed an eating disorder. She was admitted to hospital on several occasions and her condition had always improved after treatment, her family said.Her stepfather Max Figueiredo said it was a question of managing her illness and "trusting the medical profession to make the right decisions".
Mrs Figueiredo says she raised concerns about her daughter's care verbally and in writing on a number of occasions to the hospital and to Mr Aninakwa.After Alice died, she said the family found it very difficult to get answers about what happened.For nearly a decade they gathered evidence and pressed both the police and the Crown Prosecution Service (CPS) to take action.
NELFT is only the second NHS trust in England to have been charged with corporate manslaughter, with the only previous prosecution collapsing after two weeks. It is particularly hard to bring corporate manslaughter charges against a large, complex organisation, says Dr Victoria Roper – an associate professor at Northumbria University, who studies this area of the law.This is due to their complex organisational structures, says Dr Victoria Roper, a corporate lawyer and associate professor at Northumbria University.Corporate manslaughter charges are "reserved for the very worst management failings leading to death," she says.The larger the organisation, the more difficult it is to show that senior management have had "any hands-on involvement in events".However, she says public bodies, the police and the CPS will be keeping a close eye on this case to see what can be learned from it.
'Justice, truth and accountability'
Mental health campaigners believe Alice's case highlights the poor care too many mental health patients receive.Lucy Schonegevel, director of policy and practice at the mental health charity Rethink, says it is a "devastating reminder that we don't yet have a mental health system fit for the 21st century" and "people expect to be looked after and kept safe" on an inpatient unit.But she says the charity is aware of many cases of patients being failed.Alice's family believes any failing in cases such as hers must be transparent if they are to lead to improvements in mental health care, and they say they will keep pressing for that."It's never been about vengeance," Mr Figueiredo says."It's always been about justice and truth and accountability. "That's what has driven us."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Southampton lung expert warns indoor air pollution is being overlooked
Southampton lung expert warns indoor air pollution is being overlooked

BBC News

time27 minutes ago

  • BBC News

Southampton lung expert warns indoor air pollution is being overlooked

A leading respiratory expert has warned the dangers of indoor air pollution are being respiratory physician Dr Thom Daniels, from University Hospital Southampton (UHS), says the "invisible threat" may pose an even bigger risk to health than outdoor can trigger short-term respiratory symptoms and make existing conditions such as asthma warning comes as the Royal College of Physicians (RCP) publishes a new report linking air pollution to 30,000 deaths a year in the UK. "We know so much more about outdoor air pollution because it's so much easier to study," says Dr Daniels. "One monitor allows you to know about the air quality for thousands of people. But every single house is different and we spend 90% of our time indoors and until we understand better about indoor air quality, we'll be missing the majority of our air exposure." Particulates and harmful gases come from daily activities within the home such as cooking or using wood burning and other household cleaning products can also add to the problem. People with chronic lung conditions are advised to limit their use where possible."Burning your cooking on your hob really produces a lot of the very small material, particulate matter," continues Dr Daniels."Dust is unavoidable, there's always going to be dust. Cleaning products produce chemicals in the air."And another area that is really important is wood burning stoves. Everyone loves a wood burning stove - it's so lovely - but it really does produce a lot of indoor air pollution as well as outdoor." To understand how indoor air quality can be affected by everyday household tasks, I've borrowed an air monitor from Dr app tells me the air outside is good quality scoring 97 out of a possible 100. The higher the number the less measurable pollution is start with my indoor reading is about the same but it does not take long for things to go a piece of salmon, I light a fragranced candle to disguise the smell. A bit of vacuuming and spraying down the kitchen counter are also on the chores but surely the air quality starts to fall. Without burning the food it is down to 49 out of 100 - telling me the air quality is house just smells of cooking. I've never before thought of it as poor air quality. How low can you go? Curious to see what the monitor would show I decide to put two slices of bread into the toaster and crank it long whisps of smoke begin to fill the kitchen and the air quality is not long before the smoke alarm sounds and the smell of burned toast fills the entire indoor air monitor now reads zero, warning of severe pollution and telling me patients and members of sensitive groups may have to take emergency action. While poor air quality in the home is linked to household activities, which are usually short term, there is concern spikes in indoor air pollution could still be harmful."We do know that these spikes can induce changes in our bodies - so inflammation in the airways, in the cells of our airways and damage to the integrity of those airways to prevent other things getting in," warns Dr there is action you can take to reduce the levels of indoor pollution in your recommend always using an extractor fan when cooking and using the rear of the hob so that fumes go up the wall into the fan rather than towards the only dry, untreated wood at a high temperature will also help reduce emissions from wood the meantime, Dr Daniels is calling for more research into indoor air pollution to understand the problem we are all living with. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.

Dudley MP proud to lead first incontinence debate in Commons
Dudley MP proud to lead first incontinence debate in Commons

BBC News

time27 minutes ago

  • BBC News

Dudley MP proud to lead first incontinence debate in Commons

A Labour MP has said she is proud to be leading a debate about incontinence that is the first of its kind in the House of Kumar, MP for Dudley, will chair the backbench business committee debate on Thursday, which will shine a light on the issues faced by those with pelvic health issues. Kumar said the issue "affected millions across the UK", however it remained "overlooked and under-discussed". She hoped the debate would help to bring incontinence "out of the shadows" and give it the "attention it deserves". The National Institute for Health and Care estimates that 34% of women had urinary Dudley MP, who is a physiotherapist, said she had worked closely with women to help them manage the challenges of pelvic floor had previously spoken about pelvic health during a Westminster debate on women's health and received a "wave of responses" from people who had similar experiences."These are not just medical conditions, they are deeply personal challenges that can significantly impact individuals' dignity, independence, and mental wellbeing," Kumar said. Mum-of-four Leanne Shakespeare, 51, said she experienced incontinence for nearly 30 years after she had a breach birth. "I have to wear towels when I leave the house, I'd love to go swimming again but I can't. "When I'm on holiday I couldn't take my shorts off or go in the water."Ms Shakespeare, who is from Kingswinford, said it had impacted her confidence and mental health. She added that it had taken her 10 years to tell anyone what she had experienced."It's a taboo and it isn't talked about enough, now I just have to get on with it and try not to let it stop me."Ms Shakespeare said the debate was a "great idea" and she planned to "follow it on TV". Polly Weston, co-chair of the Association for Continence Professionals, was pleased that the issue had "finally gained traction". "The government is talking about something that the nation is secretly trying to deal with", she said."People will quite happily talk about other medical problems, but the minute you talk about your bowels or bladder, it doesn't seem to be a conversation." Ms Weston said she had spoken to cancer patients who found it "more complex" to talk about their bladder and bowels than the treatment they had received. She added that the privacy towards incontinence was "culture and learnt behaviour" and called for health professionals to "ask patients more open questions" about the issue. Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.

Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost
Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost

ITV News

time29 minutes ago

  • ITV News

Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost

Two drugs to treat Alzheimer's disease have been rejected for use on the NHS because their benefits are 'too small' to justify their cost, the health spending watchdog has said. The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them Professor Fiona Carragher, Alzheimer's Society She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately Hilary Evans-Newton, Alzheimer's Research UK 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store